Omalizumab
Monoclonal antibody medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Omalizumab?
Summarize this article for a 10 year old
Omalizumab, sold under the brand name Xolair, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives),[9][10] and immunoglobulin E-mediated food allergy.[11]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IgE Fc region |
Clinical data | |
Pronunciation | /ˌoʊməˈlɪzumæb/ OH-mə-LI-zoo-mab |
Trade names | Xolair |
Biosimilars | Omlyclo[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603031 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 26 days |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6450H9916N1714O2023S38 |
Molar mass | 145058.53 g·mol−1 |
NY (what is this?) (verify) |
Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.[12][13] Its primary adverse effect is anaphylaxis.
In 1987 Tanox filed its first patent application on the anti-IgE drug candidates. It took until 2003, in the United States until omalizumab was approved, in Europe until 2005 for moderate to severe persistent asthma, severe chronic rhinosinusitis with nasal polyps. In February 2024, the FDA approved it also to treat severe food allergy.